P11

CAS No. 848644-86-0

P11 ( )

Catalog No. M30577 CAS No. 848644-86-0

Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    P11
  • Note
    Research use only, not for human use.
  • Brief Description
    Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic.
  • Description
    Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic.
  • Synonyms
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    848644-86-0
  • Formula Weight
    720.8
  • Molecular Formula
    C30H48N12O9
  • Purity
    >98% (HPLC)
  • Solubility
    water:2 mg/mL
  • SMILES
    [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(N)=O
  • Chemical Name

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee et al (2004) High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J.Biomol.Screen. 9 687 PMID:
molnova catalog
related products
  • OSU-T315 (15-regiois...

    OSU-T315 (15-regioisomer) is a ILK inhibitor.

  • RGD peptide GRGDNP(2...

    RGD peptide GRGDNP(2TFA) is a integrin-ligand interactions?inhibitor.

  • Echistatin, α1 isofo...

    Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.